Dr Jason Westin spoke to Donna Gairns, National Nurse Manager during the meeting, who is the leader of the diffuse large B-cell lymphoma research team at the University of Texas MD Anderson Cancer Center. His research interests include designing and conducting innovative clinical trials, the development of new drugs and new methods to improve outcomes for patients with lymphoma.

Dr Westin discussed some of the highlights from the conference in DLBCL including CAR T-cell therapy and updates from studies that use less chemotherapy and therefore improving the toxic side effects for patients.

Dr Westin discussed his poster presentation of a study conducted at MD Anderson Cancer Centre for patients with non-GCB subtype of diffuse large B-cell lymphoma.

Smart Start: phase II study of Rituximab, Lenalidamide and Ibrutinib

Diffuse Large B-cell Lymphoma (DLBCL), the most common lymphoid cancer, is classified by the cell of origin into the germinal and non-germinal centre (non-GCB) subtypes. The non-GCB subtype is associated with inferior outcomes with standard therapies, but the BTK inhibitor ibrutinib (I) and immunomodulatory agent lenalidomide (L) have moderate activity as single agents and result in synthetic lethality when combined in non-GCB DLBCL models (Yang, Cancer Cell 2012). When added to chemotherapy for DLBCL as single agents, neither I nor L have significantly improved outcomes over chemotherapy alone as they only result in synthetic lethality with each other.

The ORR for 2 cycles of RLI alone was 86% (n=50), the CRR was 36% (n=21), and patients achieving a PR had an 81% median tumour reduction from baseline. The end of therapy ORR is 100% (CR: 95%, PR 5%), with none of the PR patients having relapsed to date without further therapy. The median follow-up at abstract submission is 16 months (1 - 33.5m), with 1 year PFS estimate of 92.5% and OS estimate of 96.5%. Response and survival were not different based upon chemotherapy selected, baseline clinical or pathological variables including DE status or Ki-67%, or number of cycles of therapy received.
[ Ссылка ]

свернуть